P&G Intrinsa Could Inaugurate Female Sexual Dysfunction Market In 2005
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Procter & Gamble’s Intrinsa could be the first treatment for female sexual dysfunction to reach the market, with potential approval as early as 2005.
You may also be interested in...
Intrinsa aftershocks?
BioSante will meet with FDA in the first quarter to discuss the status of its female sexual dysfunction product LibiGel, the firm said upon announcement of P&G's withdrawal of its FSD patch Intrinsa. BioSante is planning to begin Phase III trials of its testosterone gel. Other firms have been counting on Intrinsa to pave the way for their FSD submissions (1Pharmaceutical Approvals Monthly July 1, 2004, p. 24)...
Intrinsa aftershocks?
BioSante will meet with FDA in the first quarter to discuss the status of its female sexual dysfunction product LibiGel, the firm said upon announcement of P&G's withdrawal of its FSD patch Intrinsa. BioSante is planning to begin Phase III trials of its testosterone gel. Other firms have been counting on Intrinsa to pave the way for their FSD submissions (1Pharmaceutical Approvals Monthly July 1, 2004, p. 24)...
Alista female sexual dysfunction program
Vivus initiates Phase III trial of its topical alprostadil Alista for treatment of female sexual arousal disorder, the firm announces Sept. 7. Alprostadil, a synthetic prostaglandin, is the same active ingredient found in the company's male erectile dysfunction product Muse. Vivus expects two to four trials in 1,500-2,000 patients will support the Alista NDA, which will be submitted in late 2006 or in 2007 (1Pharmaceutical Approvals Monthly July 1, 2004, p. 24). The firm also has a testosterone spray slated to enter Phase III in 2005...